Adipotide

What is Adipotide?#

Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide) or Prohibitin-Targeting Peptide 1, is an experimental peptidomimetic compound developed to combat obesity through a novel vascular-targeting mechanism. Unlike traditional weight loss compounds that act on appetite or metabolism systemically, adipotide was designed to selectively destroy the blood vessels that supply white adipose tissue, causing targeted fat cell death through ischemia and apoptosis.

The compound was originally developed by a research team led by Dr. Wadih Arap and Dr. Renata Pasqualini at the University of Texas M.D. Anderson Cancer Center, with the foundational discovery published in Nature Medicine in 2004. The approach emerged from the broader field of vascular-targeted therapy, previously explored in oncology for tumor vasculature destruction.

Mechanism of Action#

Adipotide operates through a two-component mechanism that combines vascular targeting with programmed cell death induction.

Vascular Homing Domain#

The first component is the cyclic peptide motif CKGGRAKDC, identified through in vivo phage display screening. This peptide selectively binds to prohibitin, a receptor expressed on the surface of endothelial cells in white adipose tissue vasculature. The CKGGRAKDC motif also shows affinity for the ANXA2 (Annexin A2)-prohibitin receptor complex, which is preferentially expressed on the blood vessels feeding white fat depots.

Proapoptotic Domain#

The second component is D(KLAKLAK)2, an amphipathic D-enantiomer peptide that disrupts mitochondrial membranes upon cellular internalization. Once the homing domain delivers the compound to adipose vasculature endothelial cells and receptor-mediated endocytosis occurs, the proapoptotic domain triggers mitochondrial membrane depolarization and initiates programmed cell death.

Downstream Effects#

The destruction of adipose vasculature leads to ischemic injury in the surrounding white adipocytes, which then undergo secondary cell death. The dead adipose tissue is subsequently cleared by the immune system through phagocytic mechanisms. This cascade results in a net reduction of white adipose tissue mass, including both subcutaneous and visceral fat depots.

Research Overview#

Mouse Studies#

The foundational 2004 study by Kolonin et al. demonstrated that daily administration of the CKGGRAKDC-GG-D(KLAKLAK)2 peptidomimetic to diet-induced obese mice resulted in approximately 30% weight reduction over 4 weeks. The weight loss was attributed to selective ablation of white adipose tissue vasculature, with minimal effects on other organ vasculature.

A 2010 study by Kim, Woods, and Seeley further characterized the metabolic effects, showing that the peptide reduced food intake and body weight in obese mice fed a high-fat diet, completely reversing obesity within 27 days. A subsequent 2012 study demonstrated rapid, weight-independent improvement of glucose tolerance, with decreased serum insulin and triglycerides, suggesting direct metabolic effects beyond simple fat mass reduction.

Primate Studies#

The landmark 2011 study by Barnhart et al., published in Science Translational Medicine, evaluated adipotide in spontaneously obese rhesus monkeys. Treatment induced targeted apoptosis within white adipose tissue blood vessels and resulted in significant weight loss with improved insulin resistance. MRI and DEXA confirmed marked reduction in white adipose tissue, with a 38.7% decrease in total body fat from baseline to the end of the recovery period. Treated monkeys showed approximately 50% reduction in insulin requirements, indicating substantial metabolic improvement.

Safety Observations#

The primary safety concern identified in preclinical studies is renal toxicity. The primate study noted predictable, dose-dependent, and largely reversible renal injury characterized by altered tubular function. This renal effect is believed to result from the proapoptotic domain affecting kidney tubular endothelium, and represents a significant barrier to clinical translation.

Current Research Status#

Adipotide remains in the preclinical stage of development. No human clinical trials have been conducted or registered. The renal toxicity observed in primate studies represents a major challenge for advancing this compound toward clinical use. Research continues in the areas of improving selectivity, reducing off-target effects, and exploring modified versions of the peptidomimetic with improved safety profiles.

Important Considerations#

Adipotide is an experimental research compound that has not been approved for human use by any regulatory agency. All available data come from animal studies, and the translation of these findings to humans remains uncertain. The observed renal toxicity in primates is a significant concern. Researchers should exercise caution in interpreting preclinical results and should not extrapolate dosing or efficacy data to human applications without proper clinical validation.

Key Research Findings#

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys, published in Science Translational Medicine (Barnhart KF et al., 2011; PMID: 22072637):

• The study demonstrated decrease of 38.7% in total body fat percentage
• The study demonstrated reduction of 50% in insulin requirements

Related Reading#

• Adipotide research studies and evidence
• Adipotide dosing protocols
• Adipotide side effects profile
• AOD-9604 research guide
• Cagrilintide research guide